Hydroxychloroquine Improves the Disease Activity and Allows the Reduction of the Corticosteroid Dose Regardless of Background Treatment in Japanese Patients with Systemic Lupus Erythematosus

OBJECTIVE: Hydroxychloroquine (HCQ) was not approved in Japan until 2015, and its therapeutic potential has not been explored in depth. We evaluated the additional therapeutic effect of HCQ in Japanese patients with systemic lupus erythematosus (SLE) on maintenance therapy. METHODS: Patients with SL...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanaoka, Hironari, Iida, Harunobu, Kiyokawa, Tomofumi, Takakuwa, Yukiko, Kawahata, Kimito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543229/
https://www.ncbi.nlm.nih.gov/pubmed/30626831
http://dx.doi.org/10.2169/internalmedicine.1999-18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543229/
https://www.ncbi.nlm.nih.gov/pubmed/30626831
http://dx.doi.org/10.2169/internalmedicine.1999-18

Ejemplares similares